Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis
Authors:
- Rina AharoniRARina Aharoni
- Ravit SaadaRSRavit Saada
- Raya EilamRERaya Eilam
- Liat HayardenyLHLiat Hayardeny
- Michael SelaMSMichael Sela
- Ruth ArnonRARuth Arnon
- 1 October 2012
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 251 (1-2) , 14-24
Abstract
No abstract availableKeywords
Funding Information
- Teva Pharmaceutical Industries (Israel)
This publication has 25 references indexed in Scilit:
- Placebo-Controlled Trial of Oral Laquinimod for Multiple SclerosisNew England Journal of Medicine, 2012
- Insight into the mechanism of laquinimod actionJournal of the Neurological Sciences, 2011
- Linkage between immunomodulation, neuroprotection and neurogenesisDrug News & Perspectives, 2009
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyThe Lancet, 2008
- The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis miceProceedings of the National Academy of Sciences, 2005
- Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetateJournal of Neuroimmunology, 2005
- Neurogenesis and Neuroprotection Induced by Peripheral Immunomodulatory Treatment of Experimental Autoimmune EncephalomyelitisThe Journal of Neuroscience, 2005
- New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosisImmunology Letters, 2005
- Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the diseaseJournal of the Neurological Sciences, 2003
- The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2002